Exploring the effectiveness of a regional nurse practitioner led, long-acting injectable buprenorphine-based model of care for opioid use disorder.
buprenorphine
injectable
nurse practitioners
nurse-led clinics
opioid substitution treatment
opioid-related disorders
Journal
International journal of mental health nursing
ISSN: 1447-0349
Titre abrégé: Int J Ment Health Nurs
Pays: Australia
ID NLM: 101140527
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
revised:
02
04
2023
received:
06
02
2023
accepted:
05
04
2023
medline:
18
7
2023
pubmed:
19
4
2023
entrez:
18
4
2023
Statut:
ppublish
Résumé
The introduction of long-acting injectable buprenorphine preparations for opioid use disorder has been widely heralded as a breakthrough treatment, with several studies indicating positive results when using these medications. In many locations, nurse practitioners prescribe, administer, and monitor long-acting injectable preparations. The objective of this paper is to explore whether a reduction in dispensed needles and syringes is attributable to increased nurse practitioner prescribing of LAIB. We used a retrospective audit of needles dispensed through the health service needle and syringe program vending machine, and individuals treated with long-acting injectable buprenorphine by the nurse practitioner led model. In addition, we examined potential factors that may influence changes in the number of needles dispensed. Linear regression found that each individual with opioid dependence treated with long-acting injectable buprenorphine was associated with 90 fewer needles dispensed each month (p < 0.001). The nurse practitioner led model of care for individuals with opioid dependence appears to have influenced the number of needles dispensed at the needle and syringe program. Although all confounding factors could not be discounted entirely, such as substance availability, affordability, and individuals obtaining injecting equipment elsewhere, our research indicates that a nurse practitioner led model of treating individuals with opioid use disorder influenced needle and syringe dispensing in the study setting.
Substances chimiques
Buprenorphine
40D3SCR4GZ
Types de publication
Journal Article
Langues
eng
Pagination
1129-1137Subventions
Organisme : Indivior
Informations de copyright
© 2023 The Authors. International Journal of Mental Health Nursing published by John Wiley & Sons Australia, Ltd.
Références
Akyar, S., Nyaku, A., Lao, K., Ruthberg, S. & Zerbo, E.A. (2022) Satisfaction with group-based appointments among patients with opioid use disorder in an urban buprenorphine clinic. Substance Abuse, 43(1), 913-916. Available from: https://doi.org/10.1080/08897077.2021.2010258
Andrada, E., Rodriguez, M., Bandalan, J., Dangelo-Kemp, D., Johnston, L. & Wilson, H. (2022) Retention rates with monthly depot buprenorphine in general practice in Melbourne, Australia. Australian Journal for General Practitioners, 51, 447-451. Available from: https://doi.org/10.31128/AJGP-07-21-6098
Arunogiri, S. & Lintzeris, N. (2021) Depot buprenorphine during COVID-19 in Australia: opportunities and challenges. Journal of Substance Abuse Treatment, 124, 108221. Available from: https://doi.org/10.1016/j.jsat.2020.108221
Australian Institute of Health and Welfare. (2022) National Opioid Pharmacotherapy Statistics Annual Data collection. Canberra: Australian Government. Available from: https://www.aihw.gov.au/getmedia/e3dcfde7-bfb1-449c-a216-73f86b95b6e9/National-Opioid-Pharmacotherapy-Statistics-Annual-Data-collection.pdf.aspx?inline=true
Barnett, A., Savic, M., Lintzeris, N., Bathish, R., Arunogiri, S., Dunlop, A.J. et al. (2021) Tracing the affordances of long-acting injectable depot buprenorphine: a qualitative study of patients' experiences in Australia. Drug and Alcohol Dependence, 227, 108959. Available from: https://doi.org/10.1016/j.drugalcdep.2021.108959
Carroll, E. (2022) Implementation of office-based buprenorphine treatment for opioid use disorder. Journal of the American Association of Nurse Practitioners, 34(1), 196-204. Available from: https://doi.org/10.1097/JXX.0000000000000588
Central Gippsland Health Service. (2019) Strategic plan 2019-2024. Victoria: Central Gippsland Health. Available from: https://www.cghs.com.au/wp-content/uploads/2020/02/CGHS-2019-24-Strategic-Plan.pdf
Cheng, A., Badolato, R., Segoshi, A., McDonald, R., Malone, M., Vasudevan, K. et al. (2022) Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study. Addiction Science & Clinical Practice, 17(1), 4. Available from: https://doi.org/10.1186/s13722-022-00288-4
Grant, J., Lines, L., Darbyshire, P. & Parry, Y. (2017) How do nurse practitioners work in primary health care settings? A scoping review. International Journal of Nursing Studies, 75, 51-57. Available from: https://doi.org/10.1016/j.ijnurstu.2017.06.011
Harney, B.L., Brereton, R., Whitton, B., Pietrzak, D., Paige, E., Roberts, S.K. et al. (2021) Hepatitis C treatment in a co-located mental health and alcohol and drug service using a nurse-led model of care. Journal of Viral Hepatitis, 28(5), 771-778. Available from: https://doi.org/10.1111/jvh.13487
Heale, R., James, S., Wenghofer, E. & Garceau, M.-L. (2018) Nurse practitioner's perceptions of the impact of the nurse practitioner-led clinic model on the quality of care of complex patients. Primary Health Care Research & Development, 19(6), 553-560. Available from: https://doi.org/10.1017/S1463423617000913
Johnson, B., Flensburg, O.L. & Capusan, A.J. (2022) Patient perspectives on depot buprenorphine treatment for opioid addiction - a qualitative interview study. Substance Abuse Treatment, Prevention, and Policy, 17(1), 40. Available from: https://doi.org/10.1186/s13011-022-00474-2
Lintzeris, N., Deacon, R.M., Hayes, V., Cowan, T., Mills, L., Parvaresh, L. et al. (2022) Opioid agonist treatment and patient outcomes during the COVID-19 pandemic in south East Sydney, Australia. Drug and Alcohol Review, 41(5), 1009-1019. Available from: https://doi.org/10.1111/dar.13382
Lintzeris, N., Dunlop, A. & Masters, D. (2019) Clinical guidelines for use of depot buprenorphine (Buvidal® and Sublocade®) in the treatment of opioid dependence. New South Wales: NSW Ministry of Health. Available from: https://www.health.nsw.gov.au/aod/Publications/full-depot-bupe-interim-gl.pdf
Lofwall, M.R. & Fanucchi, L.C. (2021) Long-acting buprenorphine injectables: opportunity to improve opioid use disorder treatment among rural populations. Preventive Medicine, 152, 106756. Available from: https://doi.org/10.1016/j.ypmed.2021.106756
Martin, E., Maher, H., McKeon, G., Patterson, S., Blake, J. & Chen, K.Y. (2022) Long-acting injectable buprenorphine for opioid use disorder: a systematic review of impact of use on social determinants of health. Journal of Substance Abuse Treatment, 139, 108776. Available from: https://doi.org/10.1016/j.jsat.2022.108776
Matheson, C., Foster, R., Schofield, J. & Browne, T. (2022) Long-acting depot buprenorphine in people who are homeless: views and experiences. Journal of Substance Abuse Treatment, 139, 108781. Available from: https://doi.org/10.1016/j.jsat.2022.108781
McDonough, M. (2013) Opioid treatment of opioid addiction. Australian Prescriber, 36(3), 83-87. Available from: https://doi.org/10.18773/austprescr.2013.033
Moldestad, M., Greene, P.A., Sayre, G.G., Neely, E.L., Sulc, C.A., Sales, A.E. et al. (2020) Comparable, but distinct: perceptions of primary care provided by physicians and nurse practitioners in full and restricted practice authority states. Journal of Advanced Nursing, 76(11), 3092-3103. Available from: https://doi.org/10.1111/jan.14501
Platt, L., Minozzi, S., Reed, J., Vickerman, P., Hagan, H., French, C. et al. (2018) Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane review and meta-analysis. Addiction, 113(3), 545-563. Available from: https://doi.org/10.1111/add.14012
Turning Point. (2022) AODstats. Available from: https://aodstats.org.au/. [Accessed 15th December 2022].
Pressley Byrd, D., Galvin, S., Ramage, M. & Johnson, E. (2022) Advanced practice provider-led medication for opioid use disorder programs for pregnant and parenting women. Journal of Midwifery & Women's Health, 67(3), 384-393. Available from: https://doi.org/10.1111/jmwh.13372
Price, O., Man, N., Bruno, R., Dietze, P., Salom, C., Lenton, S. et al. (2022) Changes in illicit drug use and markets with the COVID-19 pandemic and associated restrictions: findings from the ecstasy and related drugs reporting system, 2016-20. Addiction, 117(1), 182-194. Available from: https://doi.org/10.1111/add.15620
Roberts, J., White, B., Attalla, D., Ward, S. & Dunlop, A.J. (2021) Rapid upscale of depot buprenorphine (CAM2038) in custodial settings during the early COVID-19 pandemic in New South Wales, Australia. Addiction, 116(2), 426-427. Available from: https://doi.org/10.1111/add.15244
Saunders, E.C., Moore, S.K., Walsh, O., Metcalf, S.A., Budney, A.J., Scherer, E. et al. (2020) Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders. Journal of Substance Abuse Treatment, 111, 54-66. Available from: https://doi.org/10.1016/j.jsat.2020.01.009
Seale, C., Anderson, E. & Kinnersley, P. (2006) Treatment advice in primary care: a comparative study of nurse practitioners and general practitioners. Journal of Advanced Nursing, 54(5), 534-541. Available from: https://doi.org/10.1111/j.1365-2648.2006.03865.x
Searby, A. & Burr, D. (2021) The impact of COVID-19 on alcohol and other drug nurses' provision of care: a qualitative descriptive study. Journal of Clinical Nursing, 30(11-12), 1730-1741. Available from: https://doi.org/10.1111/jocn.15732
Searby, A., Burr, D., Blums, C., Harrison, J. & Smyth, D. (2023) Barriers and facilitators to becoming an alcohol and other drug nurse practitioner in Australia: a mixed methods study. International Journal of Mental Health Nursing. Available from: https://doi.org/10.1111/inm.13125
Sorrell, T.R., Weber, M., Alvarez, A., Beste, N., Hollins, U., Amura, C.R. et al. (2020) From policy to practice: pilot program increases access to medication for opioid use disorder in rural Colorado. Journal of Substance Abuse Treatment, 114, 108027. Available from: https://doi.org/10.1016/j.jsat.2020.108027
Suzuki, J., Zinser, J., Klaiber, B., Hannon, M., Grassi, H., Spinosa, M. et al. (2015) Feasibility of implementing shared medical appointments (SMAs) for office-based opioid treatment with buprenorphine: a pilot study. Substance Abuse, 36(2), 166-169. Available from: https://doi.org/10.1080/08897077.2014.998400
Treloar, C., Lancaster, K., Gendera, S., Rhodes, T., Shahbazi, J., Byrne, M. et al. (2022) Can a new formulation of opiate agonist treatment alter stigma?: place, time and things in the experience of extended-release buprenorphine depot. International Journal of Drug Policy, 107, 103788. Available from: https://doi.org/10.1016/j.drugpo.2022.103788
Victoria State Government Department of Health. (2022) Needle and Syringe Program locations. Available from: https://www.health.vic.gov.au/aod-treatment-services/needle-and-syringe-program. [Accessed 15th December 2022].
Victorian Government Department of Health. (2021) Long-acting injectable burprenorphine: brief clinical guidelines for use in the treatment of opioid dependence. Victoria: Victorian Government. Available from: https://www.health.vic.gov.au/publications/long-acting-injectable-buprenorphine
Weeks, A., Cogger, S. & Clark, N. (2021) Initial experience with subcutaneous depot buprenorphine in a medically supervised injecting facility. Drug and Alcohol Review, 40(7), 1354-1355. Available from: https://doi.org/10.1111/dar.13291
Wellington Shire Council. (2020) Healthy Wellington 2021-2025: Municipal Scan. .id the populations expert. Available from: https://your.wellington.vic.gov.au/healthywellington. [Accessed 15th December 2022].